MARKET

ALT

ALT

Altimmune
NASDAQ
5.27
-0.07
-1.31%
After Hours: 5.32 +0.05 +0.95% 19:59 12/12 EST
OPEN
5.40
PREV CLOSE
5.34
HIGH
6.03
LOW
5.25
VOLUME
6.38M
TURNOVER
--
52 WEEK HIGH
9.95
52 WEEK LOW
2.900
MARKET CAP
549.42M
P/E (TTM)
-4.9303
1D
5D
1M
3M
1Y
5Y
1D
Altimmune put volume heavy and directionally bearish
TipRanks · 3d ago
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?
NASDAQ · 3d ago
Weekly Report: what happened at ALT last week (1201-1205)?
Weekly Report · 6d ago
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company
Seeking Alpha · 12/04 16:35
BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, BankUnited, copper miners
Reuters · 12/01 18:42
BUZZ-U.S. STOCKS ON THE MOVE-Barrick Mining, Tesla, Accenture
Reuters · 12/01 14:14
Altimmune CEO Vipin Garg To Step Down; Stock Down In Pre-Market
NASDAQ · 12/01 13:07
Altimmune Taps Board Chairman to Become CEO
Dow Jones · 12/01 12:52
More
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.